Advaxis, Inc. (NASDAQ: ADXS), a clinical stage biotechnology company developing cancer immunotherapies, recently announced preclinical data on the potential use of detoxified Listeriolysin O (dtLLO) as an effective adjuvant for the development of infectious disease vaccines. Steve King, President and CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) recently updated the market and investors with comments on the company’s status and future prospects. An excerpt from those comments are in our full report. Northwest Biotherapeutics (OTCQB: NWBO) recently transitioned from the NASDAQ to the OTC Markets. Our report details the circumstances involved and looks at the OTC future of the company. Chronic pain affects an estimated 1.5 billion people worldwide. BioElectronics Corporation (OTCBB: BIEL), the maker of ActiPatch®, an advanced over-the-counter medical device, announced the publication of a clinical study, An Over-the-counter Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief, Medication Use & Their Adverse Effects, report which indicates that ActiPatch® Therapy is effective for mitigating chronic back pain and reducing medication use including opioids.

Full Biotech report and our new feature profile can be accessed at the following link free of charge. (Copy and paste to browser may be required-
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbour created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. The subject Company has not compensated Traders News Source for the creation or dissemination of this report. Traders News Source is the party responsible for issuing the press release and for hosting the full analyst report on Traders News Source website.
Traders News Source makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
Traders News Source is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Traders News Source whatsoever for any direct, indirect or consequential loss arising from the use of this document. Traders News Source expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Traders News Source does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
Source: Traders News Source

Bioelectronics (PK) (USOTC:BIEL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Bioelectronics (PK) Charts.
Bioelectronics (PK) (USOTC:BIEL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Bioelectronics (PK) Charts.